Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de seguimiento a largo plazo de pacientes que reciben onasemnogén Abeparvovec-xioi

21 de septiembre de 2026 actualizado por: Novartis Gene Therapies

Un estudio de seguimiento a largo plazo de pacientes en los ensayos clínicos para la atrofia muscular espinal que recibieron AVXS-101

This is a long-term follow-up safety and efficacy study of participants in clinical trials for spinal muscular atrophy (SMA) who were treated with onasemnogene abeparvovec-xioi. Participants will roll over from their respective previous (parent) study into this long-term study for continuous monitoring of safety as well as monitoring of continued efficacy and durability of response to onasemnogene abeparvovec-xioi treatment.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

85

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • New South Wales
      • Randwick, New South Wales, Australia, 2145
        • Sydney Children's Hospital
      • Ghent, Bélgica, 9000
        • Universitair Ziekenhuis Gent
    • Liège
      • Liège, Liège, Bélgica, B-4000
        • Centre de Référence des Maladies Neuromusculaires
    • Ontario
      • Ottawa, Ontario, Canadá, K1H8L1
        • Children's Hospital of Eastern Ontario Research Institute
    • California
      • Palo Alto, California, Estados Unidos, 94304
        • Stanford University Medical Center
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Children's Hospital Colorado
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Ann Robert H. Lurie Children's Hospital of Chicago
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • John Hopkins Hospital - David M. Rubenstein Child Health Building
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Estados Unidos, 02115
        • Boston Children's Hospital
    • Michigan
      • Grand Rapids, Michigan, Estados Unidos, 49503
        • Spectrum Health Hospitals Helen DeVos Children's Hospital
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington Unviersity School of Medicine in Saint Louis
    • New York
      • New York, New York, Estados Unidos, 10032
        • Columbia University Medical Center
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27713
        • Duke University
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Children's Hospital of Philadelphia
      • Strasburg, Pennsylvania, Estados Unidos, 17579
        • Clinic for Special Children
    • Texas
      • Dallas, Texas, Estados Unidos, 75235
        • Children's Health Specialty Center Dallas Campus
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • University of Utah Health
    • Virginia
      • Norfolk, Virginia, Estados Unidos, 23507
        • Children's Hospital of The King's Daughters
      • Richmond, Virginia, Estados Unidos, 23298
        • Virginia Commonwealth University
    • Wisconsin
      • Madison, Wisconsin, Estados Unidos, 53792
        • University of Wisconsin, Madison
      • Paris, Francia, 75012
        • Hôpital Armand Trousseau
      • Genova, Italia, 16147
        • Instituto Gianninia Gaslini
      • Milan, Italia, 20133
        • Istituto Neurologico di Ricerca
      • Milan, Italia, 20122
        • Universita Degli Studi Di Milano
    • Roma
      • Roma, Roma, Italia, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli
      • Tokyo, Japón, 162-8666
        • Tokyo Women's Medical University Hospital
      • Newcastle upon Tyne, Reino Unido, NE1 4LP
        • The Newcastle Upon Tyne Hospitals NHS Foundation Trust
    • London
      • London, London, Reino Unido, WC1N 3JH
        • Great Ormond Street Hospital for Children NHS Foundation Trust
      • Taipei, Taiwán, 10048
        • National Taiwan University Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Any participant with SMA who received onasemnogene abeparvovec-xioi gene replacement therapy in a Novartis Gene Therapies-sponsored clinical study
  • Participant/parent/legal guardian willing and able to complete the informed consent process and comply with study procedures and visit schedule

Exclusion Criteria:

  • Parent/legal guardian unable or unwilling to participate in the long-term follow-up safety study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec-xioi

Participants received treatment with IV onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi or received treatment with IT onasemnogene abeparvovec-xioi in an onasemnogene.

Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.

Otros nombres:
  • Zolgensma

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cambio desde la línea de base en las medidas de altura
Periodo de tiempo: Hasta 5 años
Hasta 5 años
Cambio desde la línea de base en las mediciones de peso
Periodo de tiempo: Hasta 5 años
Hasta 5 años
Número de participantes con medicamentos concomitantes en general y por tipo de medicamentos
Periodo de tiempo: Hasta 5 años
Hasta 5 años
Número de participantes con otras terapias para la AME en general y por tipo de medicamentos
Periodo de tiempo: Año 6 a Año 15
Año 6 a Año 15
Number of Participants Who Reach Developmental Milestones
Periodo de tiempo: Up to 5 years

Assessed via the developmental milestone checklist, formed of 10 yes/no questions. The developmental milestones are: head control, sitting with support, sitting without support, sitting without support for 30 seconds, hands-and-knees crawling, pulls to stand, standing with assistance, walking with assistance, standing alone and walking alone.

Up to 5 years
Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score
Periodo de tiempo: Up to 5 years

The HFMSE was devised for use in children with SMA to give objective information on motor ability and clinical progression. The HFMSE is formed of 33 assessments rated from 0 (unable to perform functional task) to 2 (able to perform functional task unassisted). Higher scores on the total scale of 0-66 indicates higher levels of motor ability.

Up to 5 years
Number of Participants Who Experience a Clinically Significant Change From Baseline in Pulmonary Assessment Results and Require Ventilatory Support
Periodo de tiempo: Up to 15 years

Participants will receive pulmonary assessments by a pulmonologist or appropriate clinician. Respiratory device data will be reviewed for participants receiving non-invasive ventilatory support.

Up to 15 years
Number of Participants Who Experience Swallowing Dysfunction and Require Nutritional Support
Periodo de tiempo: Up to 5 years

Assessed via the swallowing function questionnaire, formed of 4 yes/ no questions and 1 body weight question.

Up to 5 years
Number of Participants Who Experience a Clinically Significant Change from Baseline in Physical Examination Findings
Periodo de tiempo: Up to 5 years

The physical examination includes review of the following systems: head, ears, eyes, nose and throat, lungs/thorax, cardiovascular, abdomen, musculoskeletal, neurologic, dermatologic, lymphatic, and genitourinary. In addition, visual inspection of the spine, back, shoulders, and hips looking for spinal curvature and asymmetry will be carried out. Joints will be assessed for loss of mobility and contractures.

Up to 5 years
Number of Participants Who Experience a Clinically Significant Change From Baseline in Vital Signs Measurements
Periodo de tiempo: Up to 5 years

Vital sign measurements will include blood pressure, respiratory rate, pulse, axillary temperature, and pulse oximetry.

Up to 5 years
Number of Participants Who Experience a Clinically Significant Change From Baseline in Clinical Laboratory Assessments
Periodo de tiempo: Up to 5 years

Blood samples will be collected for hematology (including complete blood cell count) and chemistry.

Up to 5 years
Number of Participants Who Experience a Clinically Significant Change From Baseline in Cardiac Assessments
Periodo de tiempo: Up to 5 years

Cardiac assessments will include a 12-lead electrocardiogram, transthoracic echocardiogram and Troponin-I.

Up to 5 years
Number of Participants Who Experience a Clinically Significant Change From Baseline in Observational Phase Questionnaire Results
Periodo de tiempo: Year 6 to Year 15

The observational phase questionnaire includes 7 yes/no questions. Observation categories include: adverse events, hospitalizations, concomitant medications, ventilatory support and feeding support.

Year 6 to Year 15
Number of Participants Who Experience at Least One Serious Adverse Event (SAE)
Periodo de tiempo: Up to 15 years

An SAE is defined as any adverse event (appearance of [or worsening of any pre existing]) undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria:

  • Fatal
  • Life-threatening
  • Results in persistent or significant disability/incapacity
  • Constitutes a congenital abnormality or birth defect
  • Requires in-patient hospitalization or prolongation of existing hospitalization
  • Is medically significant e.g. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above
Up to 15 years
Number of Participants Who Experience at Least One Adverse Event of Special Interest (AESI)
Periodo de tiempo: Up to 15 years

An AESI is defined as an AE occurring during any study phase that fulfills one of the following criteria:

  • Hepatotoxicity
  • Thrombotic microangiopathy
  • Cardiac adverse events
  • Dorsal root ganglia toxicity
  • New malignancies
  • New incidence of a neurologic disorder
  • New incidence of an autoimmune disorder
  • New incidence of hematologic disorder
Up to 15 years
Change From Baseline in Bayley Scales of Infant and Toddler Development
Periodo de tiempo: Up to 42 months, 15 days of age

Third Edition (Bayley-III) to be performed in all patients up to 42 months, 15 days of age.

Up to 42 months, 15 days of age
Change From Baseline in Revised Upper Limb Module (RULM) Score
Periodo de tiempo: Up to 5 years

RULM score is based on a scale from 0 to 37 where lower scores reflect poorer upper limb functional ability.

Up to 5 years
Change From Baseline in Cogstate Computerized Cognitive Battery Performed in Age 48 Months and Older
Periodo de tiempo: Up to 5 years

The Cogstate Computerized Cognitive Battery consists of the Identification Test (scored 0 (best) to 1.5708 (worst)), the International Shopping List Test (scored 0 (worst) to 999 (best)), the International Shopping List Test-Delayed Recall (scored 0 (worst) to 999 (best)), the One Card Learning Test (scored 0 (worst) to 1.5708 (best)), and the One Back Test (scored 0 (worst) to 1.5708 (best)).

Up to 5 years
Change From Baseline in Clinical Evaluation of Language Fundamentals Fifth Edition (CELF-5) Performed in All Participants 5 to 21 Years of Age
Periodo de tiempo: Up to 5 years

The CELF-5 Following Directions and Sentence Repetition subtests use scoring that varies based on age, but will be administered to participants 5-21 years of age. The Following Directions subtest will be scored from 0-33 with higher score being more advanced and the Recalling Sentences subtest will be scored from 0-78 with higher score being more advanced.

Up to 5 years
Change From Baseline in Assessment of Caregiver Experience With Neuromuscular Disease (ACEND)
Periodo de tiempo: Up to 5 years

ACEND score is based on a scale from 1 to 41 where higher scores represent a better caregiver experience

Up to 5 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Silla de estudio: Sitra Tauscher-Wisniewski, MD, Novartis Gene Therapies, Inc.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

10 de febrero de 2020

Finalización primaria (Estimado)

31 de diciembre de 2035

Finalización del estudio (Estimado)

31 de diciembre de 2035

Fechas de registro del estudio

Enviado por primera vez

31 de julio de 2019

Primero enviado que cumplió con los criterios de control de calidad

31 de julio de 2019

Publicado por primera vez (Actual)

1 de agosto de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • AVXS-101-LT-002
  • 2019-002611-26 (Número EudraCT)
  • 205305 (Otro identificador: JapicCTI)
  • COAV101A12103 (Otro identificador: Novartis Pharmaceuticals)
  • 2019 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir